PR) (69ème section) FRANCESCHI Frédéric (PU-PH) ,
MCF) (69ème section) CHIRURGIE DIGESTIVE 5202 ,
MCF) (5ème section) ,
MCF) (5ème section) BEGE Thierry (MCU-PH) ,
MCF) 65ème section) (retraite octobre, 2016. ,
MCF) 65ème section) ,
MCF) (1ère section) ,
Gén. à mi-temps) BERLAND Yvon (PU-PH) ,
Gén. à mi-temps) BURTEY Stépahne (PU-PH) ,
Gén à mi-temps) MOAL Valérie (PU-PH) ,
Gén. à mi-temps) JOURDE CHICHE Noémie (MCU PH) ,
Professeur associé des universités mi-temps) PHILOSPHIE 17 ,
PR) (17ème section) ,
Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options, Journal of Human Hypertension, vol.11, issue.1, pp.1-8, 2009. ,
DOI : 10.1016/j.ymgme.2004.03.006
URL : http://www.nature.com/jhh/journal/v24/n1/pdf/jhh200970a.pdf
Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients, Clinical Journal of the American Society of Nephrology, vol.4, issue.10, pp.1551-1559, 2009. ,
DOI : 10.2215/CJN.03980609
URL : http://cjasn.asnjournals.org/content/4/10/1551.full.pdf
Chronic Kidney Disease Increases Risk for Venous Thromboembolism, Journal of the American Society of Nephrology, vol.19, issue.1, pp.135-175, 2008. ,
DOI : 10.1681/ASN.2007030308
URL : http://jasn.asnjournals.org/content/19/1/135.full.pdf
Major bleeding in hemodialysis patients, Clin J Am Soc Nephrol CJASN, vol.3, issue.1, pp.105-115, 2008. ,
Review on uremic toxins: Classification, concentration, and interindividual variability, Kidney International, vol.63, issue.5, pp.1934-1977, 2003. ,
DOI : 10.1046/j.1523-1755.2003.00924.x
URL : https://doi.org/10.1046/j.1523-1755.2003.00924.x
Normal and Pathologic Concentrations of Uremic Toxins, Journal of the American Society of Nephrology, vol.23, issue.7, pp.1258-70, 2012. ,
DOI : 10.1681/ASN.2011121175
URL : http://jasn.asnjournals.org/content/23/7/1258.full.pdf
The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid, Journal of the American Society of Nephrology, vol.26, issue.4, 2015. ,
DOI : 10.1681/ASN.2013121283
URL : https://hal.archives-ouvertes.fr/hal-01610425
Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis, Nephrology Dialysis Transplantation, vol.27, issue.10, pp.3816-3838, 2012. ,
DOI : 10.1093/ndt/gfs416
The Increasing Prevalence of Atrial Fibrillation among Hemodialysis Patients, Journal of the American Society of Nephrology, vol.22, issue.2, pp.349-57, 2011. ,
DOI : 10.1681/ASN.2010050459
Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial FibrillationClinical Perspective. Circulation, pp.961-70, 2014. ,
Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation, Journal of the American College of Cardiology, vol.57, issue.12, pp.1339-1387, 2011. ,
DOI : 10.1016/j.jacc.2010.12.013
URL : https://doi.org/10.1016/j.jacc.2010.12.013
Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease, Chest, vol.149, issue.4, pp.951-960 ,
DOI : 10.1378/chest.15-1719
Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis, BMC Nephrology, vol.158, issue.9, p.157, 2016. ,
DOI : 10.1093/aje/kwg231
Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis, American Heart Journal, vol.184, pp.37-46 ,
DOI : 10.1016/j.ahj.2016.09.016
Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis, Canadian Journal of Cardiology, vol.33, issue.6, pp.737-783, 2017. ,
DOI : 10.1016/j.cjca.2017.02.004
Low-Intensity Adjusted-Dose Warfarin for the Prevention of Hemodialysis Catheter Failure: A Randomized, Controlled Trial, Clinical Journal of the American Society of Nephrology, vol.6, issue.5, pp.1018-1042, 2011. ,
DOI : 10.2215/CJN.07240810
Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials, EBioMedicine, vol.8, pp.309-325 ,
DOI : 10.1016/j.ebiom.2016.04.013
Effect of Chronic Kidney Disease on Warfarin Management in a Pharmacist-Managed Anticoagulation Clinic, Journal of Managed Care Pharmacy, vol.17, issue.7, pp.523-553, 2011. ,
DOI : 10.18553/jmcp.2011.17.7.523
Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease, PLoS ONE, vol.34, issue.5, p.94420, 2014. ,
DOI : 10.1371/journal.pone.0094420.t005
WARFARIN MANAGEMENT IN HAEMODIALYSIS-ARE WE MEETING BRITISH HAEMATOLOGY SOCIETY STANDARDS?, Journal of Renal Care, vol.19, issue.5, pp.202-208, 2012. ,
DOI : 10.1681/ASN.2007030308
Determinants and measures of quality in oral anticoagulation therapy, Journal of Thrombosis and Thrombolysis, vol.146, issue.3, pp.61-67, 2007. ,
DOI : 10.7326/0003-4819-146-3-200702060-00150
Patients??? time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry, American Heart Journal, vol.170, issue.1, pp.141-148 ,
DOI : 10.1016/j.ahj.2015.03.017
Evaluating time in therapeutic range for hemodialysis patients taking warfarin, Clinical Nephrology, vol.83, issue.02, pp.80-85, 2015. ,
DOI : 10.5414/CN108400
A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, vol.69, issue.3, pp.236-245, 1993. ,
Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range, Journal of Thrombosis and Thrombolysis, vol.15, issue.3, pp.213-219 ,
DOI : 10.1023/B:THRO.0000011377.78585.63
A hemodialysis cohort study of protocol-based anticoagulation management, BMC Research Notes, vol.6, issue.11, p.66, 2017. ,
DOI : 10.2215/CJN.04550511
Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation, Nephrology Dialysis Transplantation, vol.30, issue.3, pp.491-499, 2015. ,
DOI : 10.1093/ndt/gfu334
URL : https://academic.oup.com/ndt/article-pdf/30/3/491/17172689/gfu334.pdf
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009. ,
DOI : 10.1056/NEJMoa0905561
The quality of oral anticoagulation in general practice in patients with atrial fibrillation, European Journal of Internal Medicine, vol.25, issue.3 ,
DOI : 10.1016/j.ejim.2013.12.013
Fluindione-induced immuno-allergic interstitial nephritis. NDT Plus, Feb, vol.2, issue.1, pp.72-77, 2009. ,
DOI : 10.1093/ndtplus/sfn171
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421494/pdf
Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?, European Journal of Clinical Pharmacology, vol.43, issue.1, pp.101-106, 2012. ,
DOI : 10.1046/j.1365-2125.1997.05417.x
URL : https://hal.archives-ouvertes.fr/hal-00713311
Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation, The American Journal of Cardiology, vol.112, issue.4, pp.509-521, 2013. ,
DOI : 10.1016/j.amjcard.2013.04.013
Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: A systematic review and meta-analysis, Thrombosis Research, vol.135, issue.4 ,
DOI : 10.1016/j.thromres.2015.01.029
Vascular Incompetence in Dialysis Patients?Protein-Bound Uremic Toxins and Endothelial Dysfunction. Semin Dial, pp.327-364, 2011. ,
DOI : 10.1111/j.1525-139x.2011.00925.x
URL : https://hal.archives-ouvertes.fr/hal-01610435
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney International, vol.80, issue.6, pp.572-86, 2011. ,
DOI : 10.1038/ki.2011.223